Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bacterial penicillin-binding protein

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1984

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Bone and joint infections

3

Endocarditis

3

Respiratory tract infections

3

Sepsis

3

Skin infections

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Bristol Laboratories

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

FDA UNII

3

PUBCHEM

3

MERCK INDEX

2

SMS_ID

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER BETA-LACTAM ANTIBACTERIALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Second-generation cephalosporins

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CEFORANIDE

8M1YF8951V

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Respiratory tract infections

Urinary tract infections

Bone and joint infections

Skin infections

Ceforanide is a new cephalosporin with a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, a second-generation cephalosporin, except that ceforanide is less active against mo...

st gram-positive organisms. The bactericidal activity of ceforanide results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Ceforanide is primarily indicated in conditions like bone and joint infection, endocarditis, respiratory tract infections, skin infections, surgical infections, urinary tract infection. Rash and pruritus, and nausea, vomiting and other mild gastrointestinal side effects were noted in a few of the subjects but were mild and transient.

CEFORANIDE LYSINE

X0322BT35G

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Respiratory tract infections

Urinary tract infections

Bone and joint infections

Skin infections

Ceforanide is a new cephalosporin with a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, a second-generation cephalosporin, except that ceforanide is less active against mo...

st gram-positive organisms. The bactericidal activity of ceforanide results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Ceforanide is primarily indicated in conditions like bone and joint infection, endocarditis, respiratory tract infections, skin infections, surgical infections, urinary tract infection. Rash and pruritus, and nausea, vomiting and other mild gastrointestinal side effects were noted in a few of the subjects but were mild and transient.

CEFORANIDE SODIUM

G0NO6PD65A

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Respiratory tract infections

Urinary tract infections

Bone and joint infections

Skin infections

Ceforanide is a new cephalosporin with a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, a second-generation cephalosporin, except that ceforanide is less active against mo...

st gram-positive organisms. The bactericidal activity of ceforanide results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Ceforanide is primarily indicated in conditions like bone and joint infection, endocarditis, respiratory tract infections, skin infections, surgical infections, urinary tract infection. Rash and pruritus, and nausea, vomiting and other mild gastrointestinal side effects were noted in a few of the subjects but were mild and transient.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1